Data Sharing, Clinical Trials, and Biomarkers in Precision Oncology: Challenges, Opportunities, and Programs at the Department of Veterans Affairs.
Cancer genomic research reveals that a similar cancer clinical phenotype (e.g., non-small cell lung cancer) can arise from various mutations in tumor DNA. Thus, organ of origin is not a definitive classification. Further, targeted therapy for cancer patients (precision oncology) capitalizes on knowledge of individual patient mutational status to deliver treatment directed against the protein products of these mutations with the goal of reducing toxicity and enhancing efficacy relative to traditional nontargeted chemotherapy.
VA Boston Healthcare System, Boston, Massachusetts, USA.
L D
LD
Fiore
VA Boston Healthcare System, Boston, Massachusetts, USA.
M T
MT
Brophy
VA Boston Healthcare System, Boston, Massachusetts, USA.
R E
RE
Ferguson
VA Boston Healthcare System, Boston, Massachusetts, USA.
C
C
Shannon
VA Boston Healthcare System, Boston, Massachusetts, USA.
S J
SJ
Turek
VA Boston Healthcare System, Boston, Massachusetts, USA.
K
K
Pierce-Murray
VA Boston Healthcare System, Boston, Massachusetts, USA.
S
S
Ajjarapu
VA Boston Healthcare System, Boston, Massachusetts, USA.
G D
GD
Huang
VA Boston Healthcare System, Boston, Massachusetts, USA.
Cse
C
Lee
VA Boston Healthcare System, Boston, Massachusetts, USA.
P W
PW
Lavori
D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence* / Q000706:statistics & numerical data; D004273:DNA, Neoplasm / Q000235:genetics; D023281:Genomics; D006801:Humans; D033181:Information Dissemination / Q000331:legislation & jurisprudence*; D008495:Medical Oncology / Q000331:legislation & jurisprudence* / Q000706:statistics & numerical data; D057285:Precision Medicine / Q000639:trends*; D014481:United States; D014493:United States Department of Veterans Affairs
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm